IT202100005027A1 - INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES - Google Patents
INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES Download PDFInfo
- Publication number
- IT202100005027A1 IT202100005027A1 IT102021000005027A IT202100005027A IT202100005027A1 IT 202100005027 A1 IT202100005027 A1 IT 202100005027A1 IT 102021000005027 A IT102021000005027 A IT 102021000005027A IT 202100005027 A IT202100005027 A IT 202100005027A IT 202100005027 A1 IT202100005027 A1 IT 202100005027A1
- Authority
- IT
- Italy
- Prior art keywords
- weight
- composition
- composition according
- doses
- optionally
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 29
- 239000003571 electronic cigarette Substances 0.000 title claims description 12
- 239000007788 liquid Substances 0.000 title description 5
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 229960002715 nicotine Drugs 0.000 claims description 6
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
- 241000208125 Nicotiana Species 0.000 claims description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 5
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 5
- 235000019568 aromas Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000002485 combustion reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004005 nitrosamines Chemical group 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/243—Nicotine
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/301—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by aromatic compounds
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
Description
Titolo: ?COMPOSIZIONE LIQUIDA DA INALAZIONE PER SIGARETTE ELETTRONICHE? Title: ?LIQUID INHALATION COMPOSITION FOR ELECTRONIC CIGARETTES?
DESCRIZIONE DESCRIPTION
Campo applicativo dell?invenzione Field of application of the invention
La presente invenzione ha per oggetto una composizione liquida da inalazione per sigarette elettroniche. The present invention relates to an inhalation liquid composition for electronic cigarettes.
Stato dell?arte State of art
L?uso delle sigarette elettroniche, il cosiddetto ?vaping?, ? ormai una pratica diffusa in tutto il mondo in sostituzione almeno parziale del fumo di sigarette. E? noto infatti che il fumo delle sigarette provoca gravi danni alla salute, non tanto a causa della nicotina, che pure ? una sostanza altamente tossica, quanto per i sottoprodotti della combustione, quali idrocarburi aromatici policiclici, catrame e monossido di carbonio, aventi spesso un marcato effetto cancerogeno. The use of electronic cigarettes, the so-called ?vaping?, ? now a widespread practice all over the world as an at least partial replacement of cigarette smoking. AND? known in fact that the smoke of cigarettes causes serious damage to health, not so much because of the nicotine, which also ? a highly toxic substance, as regards the by-products of combustion, such as polycyclic aromatic hydrocarbons, tar and carbon monoxide, often having a marked carcinogenic effect.
Nel mercato sono presenti due tipologie di fumo alternativo. Una prima tipologia ? costituita dai sistemi che prevedono un riscaldamento di tabacco ad una temperatura controllata (generalmente non superiore a 350?C), cos? da evitare gli effetti nocivi della combustione ad alta temperatura. La seconda tipologia ? data dalle cosiddette ?sigarette elettroniche? che vaporizzano un liquido comprendente, oltre ad una base atta a fornire un corpo sufficientemente denso al vapore sprigionato, anche una quantit? controllata di nicotina e di aromi di vario tipo. There are two types of alternative smoking on the market. A first type? constituted by the systems that foresee a heating of tobacco to a controlled temperature (generally not superior to 350?C), cos? to avoid the harmful effects of high temperature combustion. The second type? given by the so-called ?electronic cigarettes? which vaporize a liquid comprising, in addition to a base capable of providing a sufficiently dense body for the vapor released, also a quantity controlled nicotine and aromas of various types.
La prima tipologia, a tabacco riscaldato, ? pi? simile al fumo tradizionale, ma nonostante le temperature inferiori di combustione alcune sostanze tossiche contenute nel tabacco oltre alla nicotina vengono comunque rilasciate. Un tipico esempio sono le nitrosammine. The first type, with heated tobacco, is more similar to traditional smoking, but despite the lower combustion temperatures some toxic substances contained in tobacco in addition to nicotine are still released. A typical example is nitrosamines.
Le sigarette elettroniche sono pi? sicure in quanto non contengono tali sostanze tossiche o cancerogene, a parte una quantit? controllata di nicotina, che pu? essere aggiunta a lla composizione per fornire al fumatore l?effetto desiderato di stimolazione dei recettori nicotinici. La possibilit? di aromatizzare in vario modo la composizione costituisce un?ulteriore attrattiva. E-cigarettes are more safe as they do not contain such toxic or carcinogenic substances, apart from a quantity? controlled by nicotine, which can? be added to the composition to provide the smoker with the desired effect of stimulation of the nicotinic receptors. The possibility? to flavor the composition in various ways constitutes a further attraction.
Tuttavia, anche le sigarette elettroniche non sono prive di tossicit?. Infatti, la composizione base ? costituita per la maggior parte da una miscela di glicole propilenico e glicerolo che impartiscono, soprattutto il primo, una tossicit? sulle cellule delle vie respiratorie. However, even e-cigarettes are not free from toxicity. In fact, the basic composition? constituted for the most part by a mixture of propylene glycol and glycerol which impart, especially the first, a toxicity? on respiratory cells.
E? quindi tuttora sentito il problema di poter abbassare ulteriormente la tossicit? di una composizione per inalazione tramite sigaretta elettronica cos? da renderne il consumo prolungato molto pi? sicuro. AND? then still felt the problem of being able to further lower the toxicity? of a composition for inhalation via electronic cigarette cos? to make the prolonged consumption much more? Safe.
Sommario dell?invenzione Summary of the invention
Il suddetto problema tecnico ? sostanzialmente risolto da una composizione che comprende le caratteristiche tecniche esposte in una o pi? delle annesse rivendicazioni, le cui definizioni formano parte integrante della presente descrizione ai fini della sufficienza di descrizione. Oggetto della presente invenzione ? pertanto una composizione per inalazione tramite sigaretta elettronica comprendente le seguenti componenti: The aforementioned technical problem ? substantially solved by a composition that includes the technical characteristics set out in one or more? of the attached claims, the definitions of which form an integral part of the present description for the purposes of the sufficiency of the description. Object of the present invention ? therefore a composition for inhalation by electronic cigarette comprising the following components:
a) acqua 50-85% in peso b) 1,3-propandiolo 10-50% in peso c) opzionalmente, un conservante 0,1-0,5% in peso d) opzionalmente, sorbitolo 0,1-5% in peso e) opzionalmente, un viscosizzante 0,1-10% in peso. a) water 50-85% by weight b) 1,3-propanediol 10-50% by weight c) optionally, a preservative 0.1-0.5% by weight d) optionally, sorbitol 0.1-5% by weight weight e) optionally, a viscosifier 0.1-10% by weight.
Un ulteriore oggetto dell?invenzione ? un kit comprendente una o pi? dosi della composizione dell?invenzione ed una o pi? dosi di aromi. A further object of the invention ? a kit including one or more? doses of the composition of the invention and one or more? doses of aromas.
Ulteriori caratteristiche e vantaggi della presente invenzione appariranno maggiormente chiari dalla descrizione indicativa, e pertanto non limitativa, di forme di realizzazione preferite ma non esclusive dell?invenzione. Further characteristics and advantages of the present invention will appear more clearly from the indicative and therefore non-limiting description of preferred but not exclusive embodiments of the invention.
Descrizione dettagliata dell?invenzione Detailed description of the invention
La presente invenzione riguarda una composizione base per inalazione tramite sigaretta elettronica che non contiene glicole propilenico o glicerolo e che comprende le seguenti componenti: The present invention relates to a basic composition for inhalation by electronic cigarette which does not contain propylene glycol or glycerol and which comprises the following components:
a) acqua 50-85% in peso b) 1,3-propandiolo 10-50% in peso c) opzionalmente, un conservante 0,1-0,5% in peso d) opzionalmente, sorbitolo 0,1-5% in peso e) opzionalmente, un viscosizzante 0,1-10% in peso. a) water 50-85% by weight b) 1,3-propanediol 10-50% by weight c) optionally, a preservative 0.1-0.5% by weight d) optionally, sorbitol 0.1-5% by weight weight e) optionally, a viscosifier 0.1-10% by weight.
L?acqua ? preferibilmente acqua depurata FU. The water ? preferably purified water FU.
L?1,3-propandiolo (componente b)) ha la funzione di agente viscosizzante e carrier di aromi. L?1,3-propanediol (component b)) has the function of viscosifying agent and aroma carrier.
Il conservante (componente c)) ? preferibilmente sodio benzoato. The preservative (component c)) ? preferably sodium benzoate.
Il sorbitolo (componente d)) ha la funzione di esaltatore di aromi e di protettivo della resistenza (la cosiddetta ?coil?) della sigaretta elettronica. Sorbitol (component d)) has the function of enhancing aromas and protecting the resistance (the so-called ?coil?) of the electronic cigarette.
Il viscosizzante (componente e)) pu? essere acido jaluronico o suoi Sali, pectina o sostanze aventi un effetto similare. The viscosifier (component and)) pu? be hyaluronic acid or its salts, pectin or substances having a similar effect.
Alla composizione base come sopra delineata possono essere aggiunte una o pi? delle seguenti componenti: To the basic composition as outlined above can be added one or more? of the following components:
- nicotina in percentuale peso/volume non superiore a 0,2%; - nicotine in weight/volume percentage not exceeding 0.2%;
- aromi in percentuale in volume minore o uguale a 25%, preferibilmente minore o uguale a 10%. - flavorings in percentage by volume less than or equal to 25%, preferably less than or equal to 10%.
Gli aromi possono essere di ogni tipo normalmente usato per sigarette elettroniche, quali aromi alla frutta, al tabacco, mentolati o loro miscele. Gli aromi possono essere aggiunti ad una composizione base che non li contiene direttamente dal fumatore. The flavors can be of any type normally used for electronic cigarettes, such as fruit, tobacco, mentholated flavors or mixtures thereof. Flavors can be added to a base composition that does not contain them directly from the smoker.
PARTE SPERIMENTALE EXPERIMENTAL PART
Per studiare la potenziale irritazione cutanea delle composizioni dell?invenzione, un campione di composizione ? stato applicato tal quale su epidermide umana ricostruita (RHE) di cui ? stata successivamente valutata la vitalit? cellulare mediante test MTT. To study the skin irritation potential of the compositions of the invention, a sample of the composition ? been applied as it is on reconstructed human epidermis (RHE) of which? was subsequently evaluated the vitality? cell phone by MTT test.
L?epidermide umana ricostruita ? formata da cheratinociti umani normali coltivati su un filtro inerte di policarbonato all?interfaccia aria-liquido in un mezzo di crescita chimicamente ben definito. The reconstructed human epidermis ? formed from normal human keratinocytes grown on an inert polycarbonate filter at the air-liquid interface in a chemically well-defined growth medium.
La base chimica del test ? la riduzione dell?MTT, una sostanza gialla in soluzione, a formare cristalli di formazano color viola. Tale processo di riduzione ha luogo prevalentemente nei mitocondri ed ? altamente dipendente dall?attivit? dell?enzima mitocondriale succinico deidrogenasi. Come conseguenza di questi processi metabolici, nel giro di alcune ore appaiono cristalli viola di formazano che possono essere sciolti in isopropanolo. L?assorbanza dei cristalli solubilizzati pu? essere misurato alla lunghezza d?onda di 540 nm ed ? proporzionale al numero di cellule vive in un range lineare molto ampio. The chemical basis of the test? the reduction of MTT, a yellow substance in solution, to form purple formazan crystals. This reduction process takes place mainly in the mitochondria and is highly dependent on? activity? of the mitochondrial enzyme succinic dehydrogenase. As a result of these metabolic processes, purple formazan crystals appear within hours and can be dissolved in isopropanol. The absorbance of the solubilized crystals can? be measured at? wavelength of 540 nm and ? proportional to the number of live cells over a very broad linear range.
La riduzione della vitalit? cellulare dei tessuti trattati con il campione in esame rispetto al controllo negativo viene utilizzata per predire il potenziale di irritazione cutanea. The reduction of vitality? of tissues treated with the test sample relative to the negative control is used to predict skin irritation potential.
A questo scopo 3 tessuti RHE sono stati trattati con il prodotto testato e 3 sono stati trattati con sodio dodecilsolfato (SDS) 5% (controllo positivo). Come controllo negativo sono stati usati 3 tessuti RHE non trattati (mantenuti in D-PBS durante il periodo di incubazione). Il campione testato viene considerato irritante per la pelle se la vitalit? cellulare dei tessuti in seguito a trattamento ? ?50%. For this purpose, 3 RHE tissues were treated with the tested product and 3 were treated with 5% sodium dodecyl sulphate (SDS) (positive control). 3 untreated RHE tissues (maintained in D-PBS during the incubation period) were used as a negative control. The tested sample is considered irritating to the skin if the vitality? tissue cell following treatment ? ?50%.
Il test ? stato eseguito seguendo le linee guida UNI EN ISO 10993-10:2013. The test ? carried out following the UNI EN ISO 10993-10:2013 guidelines.
Pre-incubazione Pre-incubation
I tessuti RHE sono stati lasciati in terreno di crescita per almeno 2 ore (37?C, 5% CO2) prima del trattamento. Trattamento RHE tissues were left in growth medium for at least 2 hours (37°C, 5% CO2) before treatment. Treatment
I tessuti RHE sono stati trattati per 15 minuti con 30 ?l di sostanza secondo il seguente schema: RHE tissues were treated for 15 minutes with 30 ?l of substance according to the following scheme:
- Controllo negativo DPBS - DPBS negative control
- Controllo positivo SDS 5% - Positive control SDS 5%
- Campione testato. - Sample tested.
Ciascun esperimento ? stato condotto in triplicato. Each experiment ? was conducted in triplicate.
Lavaggi Washes
I tessuti RHE sono stati ripetutamente lavati con DPBS, allo scopo di eliminare ogni traccia delle sostanze utilizzate per i trattamenti. RHE fabrics were repeatedly washed with DPBS, in order to eliminate all traces of the substances used for the treatments.
Post-incubazione Post-incubation
I tessuti RHE sono stati trasferiti in terreno di crescita per 42 ? 2 ore (37?C, 5% CO2). RHE tissues were transferred to growth medium for 42? 2 hours (37?C, 5% CO2).
Saggio MTT MTT essay
I tessuti RHE sono stati trattati con MTT (1 mg/ml) per 3 ore ? 5 minuti (37?C, 5% CO2) e quindi i cristalli di formazano sono stati estratti in isopropanolo per 2 ore ? 5 minuti a temperatura ambiente. La lettura della densit? ottica ? stata effettuata a 540 nm. Were RHE tissues treated with MTT (1 mg/ml) for 3 hours? 5 minutes (37°C, 5% CO2) and then the formazan crystals were extracted in isopropanol for 2 hours ? 5 minutes at room temperature. The reading of the density? optics ? was performed at 540 nm.
La composizione dell?invenzione contenente ACQUA DEPURATA F.U. 50%, 1,3-PROPANDIOLO (PDO) 30%, SORBITOLO FU-Ph.Eur. E 420 0,5% (mg, polvere), SODIO BENZOATO GRANULARE EP-E 211 0,3% (mg, polvere), ? stata testata nel suddetto test MTT, risultando in una percentuale di vitalit? dei tessuti trattata di circa il 100%. The composition of the invention containing PURIFIED WATER F.U. 50%, 1,3-PROPANDIOL (PDO) 30%, SORBITOL FU-Ph.Eur. E 420 0.5% (mg, powder), SODIUM BENZOATE GRANULAR EP-E 211 0.3% (mg, powder), ? been tested in the aforementioned MTT test, resulting in a percentage of vitality? of the tissues treated by about 100%.
Pertanto, la composizione base della presente invenzione non presenta la citotossicit? tipica delle composizioni per sigarette elettroniche a base di glicole propilenico e glicerolo, rendendo quindi la pratica del ?vaping? molto pi? sicura. Therefore, the basic composition of the present invention does not exhibit the cytotoxicity? typical of propylene glycol and glycerol-based compositions for electronic cigarettes, thus making the practice of ?vaping? much more safe.
E? evidente che sono state descritte solo alcune forme particolari di realizzazione della presente invenzione, cui l?esperto dell?arte sar? in grado di apportare tutte quelle modifiche necessarie per il suo adattamento a particolari applicazioni, senza peraltro discostarsi dall?ambito di protezione della presente invenzione. AND? It is evident that only some particular embodiments of the present invention have been described, to which the expert in the art will be capable of making all the modifications necessary for its adaptation to particular applications, without however departing from the scope of protection of the present invention.
Claims (7)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000005027A IT202100005027A1 (en) | 2021-03-04 | 2021-03-04 | INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES |
| JP2023553487A JP2024508528A (en) | 2021-03-04 | 2021-12-22 | Liquid composition for electronic cigarette inhalation |
| PCT/IB2021/062189 WO2022185117A1 (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhalation for electronic cigarettes |
| KR1020237033352A KR20230154446A (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhaling electronic cigarettes |
| CA3211812A CA3211812A1 (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhalation for electronic cigarettes |
| CN202180095093.9A CN117156984A (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhalation of electronic cigarettes |
| EP21830520.9A EP4301165A1 (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhalation for electronic cigarettes |
| AU2021431664A AU2021431664A1 (en) | 2021-03-04 | 2021-12-22 | Liquid composition for inhalation for electronic cigarettes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000005027A IT202100005027A1 (en) | 2021-03-04 | 2021-03-04 | INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202100005027A1 true IT202100005027A1 (en) | 2022-09-04 |
Family
ID=75850578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102021000005027A IT202100005027A1 (en) | 2021-03-04 | 2021-03-04 | INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4301165A1 (en) |
| JP (1) | JP2024508528A (en) |
| KR (1) | KR20230154446A (en) |
| CN (1) | CN117156984A (en) |
| AU (1) | AU2021431664A1 (en) |
| CA (1) | CA3211812A1 (en) |
| IT (1) | IT202100005027A1 (en) |
| WO (1) | WO2022185117A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020089640A1 (en) * | 2018-11-01 | 2020-05-07 | Nicoventures Trading Limited | Aerosolisable formulation |
| WO2020245431A1 (en) * | 2019-06-05 | 2020-12-10 | Philip Morris Products S.A. | Nicotine composition, method for making and aerosol generating articles comprising such |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102655495B1 (en) * | 2019-06-05 | 2024-04-09 | 필립모리스 프로덕츠 에스.에이. | Liquid tobacco extract, method for producing same and aerosol-generating article containing same |
-
2021
- 2021-03-04 IT IT102021000005027A patent/IT202100005027A1/en unknown
- 2021-12-22 CA CA3211812A patent/CA3211812A1/en active Pending
- 2021-12-22 WO PCT/IB2021/062189 patent/WO2022185117A1/en active Application Filing
- 2021-12-22 AU AU2021431664A patent/AU2021431664A1/en active Pending
- 2021-12-22 EP EP21830520.9A patent/EP4301165A1/en active Pending
- 2021-12-22 KR KR1020237033352A patent/KR20230154446A/en unknown
- 2021-12-22 CN CN202180095093.9A patent/CN117156984A/en active Pending
- 2021-12-22 JP JP2023553487A patent/JP2024508528A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020089640A1 (en) * | 2018-11-01 | 2020-05-07 | Nicoventures Trading Limited | Aerosolisable formulation |
| WO2020245431A1 (en) * | 2019-06-05 | 2020-12-10 | Philip Morris Products S.A. | Nicotine composition, method for making and aerosol generating articles comprising such |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021431664A1 (en) | 2023-09-14 |
| JP2024508528A (en) | 2024-02-27 |
| WO2022185117A1 (en) | 2022-09-09 |
| CN117156984A (en) | 2023-12-01 |
| CA3211812A1 (en) | 2022-09-09 |
| EP4301165A1 (en) | 2024-01-10 |
| KR20230154446A (en) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69812387T2 (en) | SMOKING PRODUCTS CONTAINING OXIDATION INHIBITORS | |
| EP3214956B1 (en) | Solution comprising nicotine in unprotonated form and protonated form | |
| KR101208473B1 (en) | Composition of atomized solution for electronic cigarette | |
| US20070068542A1 (en) | Seven different-flavored cigarette substitute | |
| CN112674345A (en) | Cyclodextrin additive and preparation method and application thereof | |
| ES2939507T3 (en) | Aerosolizable formulation | |
| KR20210115609A (en) | Reconstituted tobacco sheet comprising clove by-products and a smoking article including the same | |
| AU2022218470A1 (en) | Vaporisable formulation | |
| IT202100005027A1 (en) | INHALATION LIQUID COMPOSITION FOR ELECTRONIC CIGARETTES | |
| CN107280065B (en) | Natural eutectic solvent humectant for smoke of amino acid pattern and its preparation method and application | |
| US20050263165A1 (en) | Tobacco leaf substitute | |
| US20090028898A1 (en) | Instant Additive Solution for the Filter of Cigarette, Its Production Method and Use | |
| CN112739223B (en) | Inhalable compositions for electronic smoking devices | |
| CN105146746B (en) | A kind of tea polyphenols tobacco humectant and the application in Medicated cigarette thereof | |
| KR20190005225A (en) | Tobacco packing for non-smoking small heating smoking articles | |
| KR100998486B1 (en) | Liquid composition of antismoking aid containing wood vinegar | |
| CN107212460B (en) | The natural eutectic solvent humectant for smoke of lemon acid type and its application in cigarette | |
| Sifola | Quality characteristics of Burley tobacco irrigated with saline water | |
| EP3939441A1 (en) | Functional material-coated tipping paper for smoking article, and method for coating tipping paper | |
| IT202000030173A1 (en) | INHALATION LIQUID COMPOSITION FOR REDUCED CYTOTOXICITY ELECTRONIC CIGARETTES | |
| RU2795122C1 (en) | Wrapping paper for smoking products coated with functional material and method for coating wrapping paper | |
| CN107136559A (en) | Natural eutectic solvent humectant for smoke of glucose-type and its preparation method and application | |
| IT202100022172A1 (en) | MEDICAL LIQUID COMPOSITION FOR AIR ADMINISTRATION | |
| Son | Estimating the human health risks associated with exposures to harmful constituents emitted from electronic cigarettes | |
| Van Amsterdam et al. | The relation between the quantity of ammonium compounds in tobacco and the nitrogen monoxide (NO) levels in the smoke of cigarettes marketed in the Netherlands |